Austria's health ministry. It publishes the National Cancer Framework Programme 2026 to 2035, hosts the oncology advisory board and the national board that assesses costly hospital medicines, and oversees the medicines authority.
The ministry published Austria's first National Cancer Framework Programme in 2014 and a second for 2026 to 2035, an expert paper written under its oncology advisory board (a commission under the Federal Ministries Act) that sets goals, measures and indicators from prevention to palliative care but deliberately names no responsibilities or milestones. The programme credits the first round with the National Screening Committee for Cancer founded in 2021, a model rulebook for tumour boards in 2015, a national information point on cancer trials in 2017 and digital-only reporting to the national cancer registry from 2019.
The ministry hosts the Bewertungsboard set up under section 62d of the federal Hospitals Act after the 2023 health reform, which first met on 11 September 2024 and recommends whether and how selected high-priced medicines should be used in hospitals; its cancer decisions include a conditional recommendation for tisotumab vedotin in cervical cancer (24 June 2026) and no recommendation for obe-cel in adults with relapsed B-cell leukaemia (19 November 2025). Statistik Austria produced the cancer forecast to 2045 on the ministry's behalf, and the medicines authority BASG is an authority under the ministry.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-11-19.
Matched to Federal Ministry of Social Affairs, Health, Care and Consumer Protection, including child institutions. 5 works · 9 citations · 60% open access · 0% clinical trials · 20% reviews.
Free vaccination alone has not brought Austrian coverage to herd immunity; the authors call for education that addresses fears of side effects and misinformation and stresses the benefit for both sexes.
An Austrian regional programme, run from 2008 before the national programme was rolled out in 2014, that adds ultrasound to mammography; the authors judge its performance favourable and its harms low compared with other European programmes.
Taking part in Tyrol's organised screening was linked with a 28% lower risk of a breast cancer of 21 mm or more and a 17% lower risk of advanced breast cancer, which the authors expect to translate into fewer breast cancer deaths.
Shares Tisotumab vedotin, Cervical cancer.
Shares Tisotumab vedotin, Colorectal cancer.
Shares Tisotumab vedotin, Cervical cancer.
Shares Tisotumab vedotin, Cervical cancer.
Shares Tisotumab vedotin, Cervical cancer.
Shares Tisotumab vedotin, Cervical cancer.
Shares Tisotumab vedotin, Cervical cancer.
Shares Lifileucel, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/